Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 5 February

Jessica Amir
February 5, 2020

Morning Bell 4 February

Jessica Amir
February 4, 2020

Morning Bell 3 February

Jessica Amir
February 3, 2020

January Market Overview

Jessica Amir
January 31, 2020

Morning Bell 31 January

Jessica Amir
January 31, 2020

Morning Bell 29 January

Jessica Amir
January 29, 2020

Morning Bell 28 January

Jessica Amir
January 28, 2020

Morning Bell 24 January

Paulina Peters
January 24, 2020

Morning Bell 23 January

Jessica Amir
January 23, 2020

Morning Bell 22 January

Jessica Amir
January 22, 2020